Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Business Of Biotech
00:00
The Rise of Emerging Biotechs
We are at a phase where we have the advent of the first wave of companies, which comes with an advent of a first kind of modality. The fact that we have many modalities it's a very good sign. We see data with product that are not donor derived, they are different products. And I would agree that sometimes it might not be sufficient. You might need our product together with an immunosuppressant, for example.
Transcript
Play full episode
